TrialBlood advances2021

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.

Christopher P Fox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.